KIT and gastrointestinal stromal tumor: Imatinib (Gleevec), a well-known inhibitor of the oncogenic Bcr-abl fusion protein responsible for chronic myelogenous leukemia (CML), has been used to target PDGFR in gastrointestinal stromal tumors KIT positive.